nivolumab plus ipilimumab (n=49) vs. nivolumab alone (n=51)
randomized controlled trial
nivolumab plus ipilimumab
fourintravenous infusions of nivolumab 3 mg/kg plus ipilimumab1 mg/kg every 3 weeks (nivolumab plus ipilimumab).
nivolumab
fourintravenous infusions of nivolumab 3 mg/kg every 2 weeks(nivolumab)
Eachinduction regimen was followed by a common maintenanceregimen: nivolumab 3 mg/kg every 2 weeks for a maximumof 42 doses.
metastatic/advanced OC (mOC) - 2nd line (L2)
open label
37 academic and community centers in the United States,
P2/ one sided (15%) and no interim analysis. An interim report will be given to the DMC once the first stage data is mature.
Compared with nivolumab alone, the combination of nivolumab and ipilimumab in EOC did not show superior in response rate, with toxicity of the combination regimen comparable toprior reports.